Physician profile
Ami Kothari
NPI 1194981100
$23,725.09
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,419 · 2020: $13K · 2021: $2,121 · 2022: $163 · 2023: $260 · 2024: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $9,170.02 | 2019-2024 | |
| Janssen Biotech, INC. | $5,367.90 | 2019-2021 | |
| Amgen INC. | $4,197.02 | 2019-2024 | Otezla, Krystexxa |
| Genzyme Corporation | $2,629.33 | 2019-2020 | |
| Pfizer INC. | $1,850.00 | 2020 | |
| Horizon Therapeutics Plc | $143.14 | 2021-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $90.87 | 2021 | |
| Abbott Laboratories | $66.58 | 2019-2020 | |
| Ucb, INC. | $56.95 | 2023-2024 | Cimzia |
| Glaxosmithkline, LLC. | $54.54 | 2022 | |
| Lilly USA, LLC | $45.81 | 2019 | |
| Ermi LLC | $19.22 | 2019 | |
| Janssen Scientific Affairs, LLC | $19.13 | 2019 | |
| Si-Bone, INC. | $14.58 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ami Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.